Patients with EGFR-mutated NSCLC who progress on first-line osimertinib live longer without disease worsening when the drug ...

Crizotinib, an approved treatment for advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC), did not improve ...

Aging is a natural process that everyone experiences, but the desire to slow its visible effects is stronger than ever.

If people with substance use disorders give up smoking, studies show their likelihood of recovery from other drugs or alcohol ...

The National Kidney Foundation of Louisiana is hosting a free kidney screening for adults on Saturday, Sept. 20 from 8:30 a.m ...

We could be proud and say this is the best massage music ever :D But instead, we only invite you to try to reach your ...

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Chemotherapy-free combination regimen has the potential to usher in new era for first-line treatment, with median overall survival projected to exceed four years, surpassing monotherapy TKI osimertini ...

Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2 ) — Crizotinib, an approved treatment for advanced ALK-positive (ALK+) non-small cell ...

Ivonescimab Plus Chemotherapy Improves Progression-Free Survival in Patients with EGFR+ NSCLC Following 3rd-Generation EGFR-TKI Therapy(Barcelona ...

One in five eligible Australian cancer patients never receives this form of treatment, according to research cited by ...